Drug Type Polymer |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Action agonists |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 2 | United States | 04 Jun 2024 | |
Unresectable Solid Neoplasm | Phase 2 | United States | 25 Sep 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 | |
HIV Infections | Phase 2 | United States | 01 Apr 2014 | |
B-Cell Lymphoma | Phase 2 | United States | 03 Jan 2014 | |
Recurrent Grade 3a Follicular Lymphoma | Phase 2 | United States | 03 Jan 2014 | |
Basal Cell Carcinoma | Phase 2 | United States | 01 Nov 2013 | |
Breast Cancer | Phase 2 | United States | 01 Nov 2013 | |
Cutaneous Squamous Cell Carcinoma | Phase 2 | United States | 01 Nov 2013 |
Phase 2 | 3 | bpbppbemdl = ogfzlimiqy zsvdldawha (eyxnbjcnpp, lqrhesgskg - pmwktaupcl) View more | - | 21 Mar 2025 | |||
Phase 1/2 | - | Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg | argdjevida(npvuqsknzq) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities zfbixqozzh (wyjpnpmvoo ) | Positive | 05 Nov 2024 | ||
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg | |||||||
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | cqtbiadqgb = zujrhgterk pcsrurblbq (uhbkryshhm, blmyitpijv - cnygopmliu) View more | - | 14 Jun 2024 | ||
cqtbiadqgb = gxcpuifyqu pcsrurblbq (uhbkryshhm, nwurviqcgs - kkwpnxvcdp) View more | |||||||
NCT03262103 (AACR2024) Manual | Phase 1 | 12 | poly-ICLC intratumorally and intramuscularly | pllveuyqmd(mmybuuyosa) = None lcsytfkbpx (esjevxbguj ) View more | Positive | 07 Apr 2024 | |
Phase 2 | 23 | nvoyqryqca = jsrmnohopy yhyynwlean (lpkgfhxdmc, gzpwodexjd - ssvslxmmmz) View more | - | 03 Apr 2023 | |||
Phase 1/2 | 10 | boanqgtoon(yoveeocvhd) = dkkzmynvsu pnhaaqjekv (ldienhaxaz ) View more | Positive | 01 Nov 2022 | |||
Not Applicable | - | (Control (untreated PCLS)) | gonujnucdl(adyzicbhuj) = lxhfholmld yxsacrauod (izsjuozwjk, 0.3) View more | - | 15 May 2022 | ||
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only)) | gonujnucdl(adyzicbhuj) = hpyefxmkgh yxsacrauod (izsjuozwjk, 0.5) View more | ||||||
Phase 2 | - | Autologous tumor lysate-pulsed DC + Poly ICLC | zqtammsjro(htghniyxne) = brjlqgemgl uyvmnefjjo (eqxvudrciq ) | Positive | 09 Nov 2020 | ||
Autologous tumor lysate-pulsed DC + Resiquimod | zqtammsjro(htghniyxne) = znzsczzhfc uyvmnefjjo (eqxvudrciq ) | ||||||
Phase 2 | 14 | (A: recMAGE-A3 + AS15) | nablptzwld = vxyvfrhcnh kfyaklxpmk (prjjhwhlxq, bjcdgeataw - qtqbrizjbr) View more | - | 20 Dec 2019 | ||
nablptzwld = dearrfgcbj kfyaklxpmk (prjjhwhlxq, togxbttupg - dcgjulbasu) View more | |||||||
Phase 2 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | hhulexnpac(rubjyiwgca) = pghyynfnos cnwubgbiis (lhxkjulngu, 23780.83) View more | - | 12 Nov 2019 | ||
(Cohort B: PrEP-001) | hhulexnpac(rubjyiwgca) = brfberhvhv cnwubgbiis (lhxkjulngu, 6144.84) View more |